ˆ Wegovy (semaglutide injection 2.4mg) is an unfunded prescription medicine - payment for this medicine and additional doctor or pharmacy fees will be required. Wegovy is used for weight loss and maintenance, in addition to diet and exercise in adults and adolescents (> 12 years) who meet certain BMI criteria. It is used as an addition to standard of care heart disease therapy to reduce the risk of serious heart events in adults with a BMI >27 kg/m2 who have heart disease without established diabetes. Wegovy has risks and benefits. Use strictly as directed. If you experience side effects see your doctor, pharmacist or healthcare professional. Please refer to the Wegovy Consumer Medicines Information available at www.medsafe.govt.nz. Wegovy is a registered trademark of Novo Nordisk A/S, Novo Nordisk Pharmaceuticals Ltd, Auckland.
